Decitabine treatment reversed cisplatin resistance in bladder cancer cells, and it was therefore suggested that HOXA9 could predict response to cisplatin-based chemotherapy in patients with bladder cancer. The gene discussed is HOXA9; the disease is urinary bladder cancer.